Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 106

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 106
---
 Cancer Incidence – United States. https://seer.cancer.gov |

| 5. | GLOBOCAN 2022. Global Pancreatic                    
 Cancer Incidence and Mortality. https://gco.iarc.fr |

| 6. | Solid Tumor Therapeutics                                                                                                        
 Market Size by Cancer Type, by Drug Type, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033”. 
 The Brainy Insights, January 2024                                                                                               |

Liposomal Protein-Loaded Technology: Scientific Background Overview

Under the agreements with Yissum, we have a broad exclusive license
for all human application utilizing liposomal based vaccines. The initial indications that we are pursuing in this regard relate to COVID
19 and West Nile virus.

Currently, there are four (4) different platforms that are used to
develop viral vaccines:

| ● | Whole virus |

| ● | Protein-based |

| ● | Viral vector |

| ● | Nucleic acid |

Virus based vaccines can be live attenuated and
inactivated.

The live attenuated vaccine (LAV) requires genetic
manipulation to develop low-replication variants of the virus that cannot cause disease but can elicit a similar immune response to that
seen in natural infections. It has been linked to genetic instability and the presence of residual virulence.

Inactivated vaccines are part of the standard
viral vaccination technique. Because these vaccines contain many antigenic components, they have the ability to elicit a wide range of
immune responses. Compared to live-attenuated vaccines, they are generally associated with lower reactogenicity but may also elicit weaker
immune responses.. For inactivated vaccines to be effective, multiple inoculations and powerful combination therapies may be required.

Protein-based vaccines

Subunit vaccines implement purified immunogenic
proteins or peptides. For example, the majority of Coronavirus (CoV) subunit vaccines target the Spike protein, particularly its receptor
binding domain (RBD) which is highly immunogenic. Vaccination targets include viral structural proteins such as small envelope protein
E, envelope spike protein S, nucleocapsid protein N, and matrix protein M. Sever Acute Respiratory Syndrome SARS-CoV RBD antibodies cross-react
with the respective protein, and the resultant antisera neutralises the virus, shows that a vaccination targeting the S protein domain
could be successful in preventing Coronavirus. The S protein of full-length i.e., S1